Eisai and Biogen (BIIB) reported new 3-year real-world LEADER findings for lecanemab (LEQEMBI) in 560 early Alzheimer’s patients across 13 U.S. sites
Eisai and Biogen (BIIB) reported new 3-year real-world LEADER findings for lecanemab (LEQEMBI) in 560 early Alzheimer’s patients across 13 U.S. sites. They cite a 76% lower progression rate to moderate/severe dementia (HR 0.24) and 81.1% stable or improved, plus amyloid clearance and ARIA rates.
How this was made
The 30-second read
Why it matters
The disclosure emphasizes slower progression to moderate or severe dementia (HR 0.24), high stability/improvement rates, high treatment persistence, and amyloid clearance, while reporting ARIA rates as consistent with prior registries and lower during subcutaneous maintenance.
Market read
Quantified real-world effectiveness and persistence metrics, plus detailed ARIA safety during maintenance (including subcutaneous), can shift investor expectations for lecanemab’s durability in routine care.
What to watch
The study is retrospective and includes modeling-based estimates (e.g., 95% estimated to remain early through 36 months), so traders may discount magnitude versus prospective trial endpoints.
Background
Eisai and Biogen are reporting updated three-year real-world results from the LEADER study of lecanemab (LEQEMBI) in early Alzheimer’s, presented at CTAD, alongside an international pooled meta-analysis.
Ticker impact
Biogen is named as co-announcer of new 3-year LEADER real-world lecanemab findings, including a 76% lower progression rate and detailed ARIA safety.
Likely upward bias as investors price in stronger real-world durability and tolerability versus prior expectations.
The article provides multiple quantified outcomes (HR 0.24, 81.1% stable/improved, 87.5% persistence, ARIA rates) that can influence sentiment around lecanemab’s commercial and clinical narrative, though it is not a regulatory decision or new trial endpoint.
Market effects
Reinforces the anti-amyloid real-world evidence narrative for Alzheimer’s disease therapeutics, potentially affecting sentiment across the AD treatment complex.
Primarily US biotech sentiment via Biogen, with additional international context from CTAD meta-analysis.
CTAD presentation and multi-country pooled safety comparisons can influence global investor perception of class-wide tolerability and persistence.
Counterpoint
Real-world, retrospective chart-based comparisons versus an external cohort may be subject to selection and documentation bias, limiting how much investors should extrapolate to future outcomes.
Key entities
- companyBiogen Inc.
Co-announcer of LEADER real-world lecanemab findings and CTAD meta-analysis; subject of the ticker extraction.
- companyEisai Co., Ltd.
Co-announcer of the LEADER real-world lecanemab findings.
- drugLEQEMBI (lecanemab)
Anti-amyloid therapy whose real-world progression, persistence, amyloid clearance, and ARIA safety are quantified.
- clinical_studyLEADER study
Retrospective real-world study using de-identified chart and EMR data across 13 US sites.
- conferenceCTAD
Conference where the international pooled real-world meta-analysis was presented.



